APGE Apogee Therapeutics, Inc. Insider Trading

CEO Michael Thomas Henderson sells 20,000 APGE shares at $133.63; stock now at $133.65 within 0.2% of 52-week high.

Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, sold 20,000 shares on 2026-07-08 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-13. The transaction was scheduled, not discretionary. This sale comes amid strong recent stock appreciation: the company's shares are up 61.6% over the last 30 days and 54.9% over 90 days, now trading at $133.65, just 0.2% below the 52-week high of $133.87. However, the broader context shows concerning fundamentals—the company reported a net loss of $-74,111,000.00 for its most recent full fiscal year. Henderson's prior five trades at APGE (all in June 2026) also showed significant post-sale appreciation at the 30-day mark, ranging from 53.8% to 61.4%, indicating a pattern of selling into rallies. His post-transaction holdings remain substantial at 920,941 shares, and the sale reduced his position by only 2.1%.

CMO Carl Dambkowski sells 5,500 APGE shares at $132.74 under pre-arranged 10b5-1 plan; stock near 52-week high of $133.85

Carl Dambkowski, Chief Medical Officer, executed a scheduled sale of 5,500 shares under a 10b5-1 trading plan adopted on 2025-09-22, reducing his non-derivative holdings from 183.4K shares to 177.9K shares while retaining 114,790 stock options. The sale occurred at $132.74, just -0.7% from the 52-week high of $133.85, amid a sharp 30-day surge of +68.9% and 90-day climb of +57.6%. The company posted a net loss of $-74.1M in its most recent full fiscal year, yet the stock has risen substantially in recent months. Dambkowski's prior APGE sales in January 2026 showed negative 30-day returns (ranging -22.3% to -19.3%) followed by positive 90-day returns (+4.0% to +8.0%), while his cross-ticker track record across 15 prior sells averaged +11.8% 30-day and +13.4% 90-day returns—though this is a scheduled transaction, not a discretionary timing signal.

CMO Carl Dambkowski sold 26.4K APGE shares at $132.60 (via 10b5-1 plan); stock now at $132.69, up 63.5% in 30 days.

Carl Dambkowski sold 26,400 shares for $3,500,640.00 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-22, reducing his holdings by 12.8% to 179,248 shares. The sale occurred at $132.60, within 0.4% of the 52-week high of $133.16, and the stock has since traded slightly higher at $132.69. His prior five trades at APGE show mixed outcomes—four consecutive sells on 2026-01-07 each posted negative 30-day returns (-21.3%, -19.3%, -20.1%, -22.3%) though longer-term 90-day returns were generally positive—suggesting execution context specific to this ticker differs from his broader cross-ticker track record (14 prior sells with +11.8% avg 30-day return). The company reported a full fiscal year net income of $-74,111,000.00, operating at a loss, which frames the sale against deteriorating fundamentals rather than discretionary conviction-driven activity.

CEO Michael Thomas Henderson sold 80,000 shares ($10.6M) at $132.54 under 10b5-1 plan; holds 1.02M post-sale in unprofitable $9.9B company.

Michael Thomas Henderson, as CEO, sold 80,000 shares (80.0K shares) for a total value of $10,603,200.00 ($10.6M) at $132.54 on 2026-06-22 under a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, reducing his holdings from 1,095,987 shares (1.10M shares) to 1,015,987 shares (1.02M shares). The sale occurs while the stock trades near its 52-week high of $133.16 (within 0.4% of peak) and after a strong 30-day surge of +63.5%, though this is a scheduled execution rather than a discretionary trade decision. Apogee Therapeutics reported a net loss of $74,111,000.00 ($-74.1M) in its most recent full fiscal year, indicating the company is unprofitable despite its market capitalization of $9,936,145,125.24 ($9.9B). The CEO's cross-ticker track record shows an average 90-day return of +22.6% after prior sells (20 prior sells across all tickers), though same-ticker measurable outcomes are not yet available for the five prior trades at APGE on 2026-06-10, making direct comparison of his historical timing accuracy at this specific ticker unavailable.

CEO Michael Thomas Henderson sold 20,000 shares of APGE for $1.7M via 6 separate transactions on 2026-06-10 under pre-arranged 10b5-1 plan.

Michael Thomas Henderson, CEO of Apogee Therapeutics, executed six separate sales totaling 20,000 shares for $1,667,621.66 on 2026-06-10, reducing his holdings by 1.8% to 1,095,987 shares. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, meaning the sales were scheduled rather than discretionary. At current price of $88.33, the stock has risen 5.2% over the prior 30 days and 22.8% over 90 days, outpacing the blended transaction average of $83.38. The company reported a negative net income of $-74,111,000.00 for its most recent full fiscal year, indicating ongoing unprofitability despite recent stock price strength. The CEO's prior trades at APGE show mixed 30-day outcomes, though the scheduled nature of this plan removes timing from the analysis equation.

CEO Henderson sells 20,000 shares ($1.6M) via pre-arranged 10b5-1 plan at APGE; stock down 9.2% in 30 days.

Michael Thomas Henderson, CEO of Apogee Therapeutics, executed 2 separate sales totaling 20,000 shares for $1,641,710.73 on 2026-05-13 at an average price of $82.09 per share. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, meaning it was scheduled in advance rather than a discretionary decision. The sale reduced his holdings from 1.14M to 1.12M shares—a modest reduction relative to his total position. The company is unprofitable with net income of $-74,111,000.00, and the stock is currently trading at $81.14, down 9.2% over the past 30 days and down 14.9% from its 52-week high of $95.32. Since this trade is scheduled under a 10b5-1 plan, it does not reflect a timing decision by the CEO; rather, it represents a pre-planned reduction in holdings that occurred while the company operates at a loss and equity is under recent downward pressure.

CEO Henderson sells 20,000 shares ($1.7M) via scheduled 10b5-1 plan; retains 1.13M shares.

Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, executed 3 separate sales totaling 20,000 shares for $1,651,664.00 on 2026-04-08 at prices ranging from $82.48 to $85.00, with a blended average price of $82.58. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, meaning it was scheduled rather than discretionary. Post-transaction, Henderson retains 1,132,987 shares, representing a -1.7% reduction in his holdings. As a scheduled divestiture under a pre-established plan, this activity does not signal timing-based conviction or concern, but rather reflects a predetermined liquidity or diversification program adopted several months prior.

CEO Henderson sold 20,000 shares (20.0K shares) for $1,495,604.52 across 3 transactions at $74.78 avg

Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, executed 3 separate sales totaling 20,000 shares for $1,495,604.52 on March 11, 2026, at a blended average price of $74.78. The company is unprofitable with a net loss of $-65,021,000.00 for its most recent full fiscal year, and the stock is currently trading at $71.90, down 12.8% from its 52-week high of $82.43. Henderson's prior sell activity at APGE has shown mixed outcomes: three recent February sales generated 30-day returns of +14.2%, +10.6%, and +12.8%, while two January sales produced -17.8% and -16.3% 30-day returns. The sale reduces his holdings by 1.7% from 1,172,987 to 1,152,987 shares, maintaining substantial position ownership while the company operates at a significant loss.

CEO Michael Thomas Henderson sells 20,000 shares at blended avg $63.35; stock now $67.78, post-sale holding 1,172,987 shares

Michael Thomas Henderson, CEO of Apogee Therapeutics, executed 3 separate sales totaling 20,000 shares for $1,266,952.92 on 2026-02-11 at prices ranging from $62.96 to $64.99. The sales reduce his post-transaction holdings to 1,172,987 shares, a -1.7% reduction from his prior position. Henderson's cross-ticker track record shows 20 prior sells with an average 90-day return of -18.1% and a 60.00% well-timed rate, indicating he has historically sold before declines across his broader portfolio. However, at APGE specifically, his 5 prior trades (all sales on 2026-01-14) are still within their 30-day windows with negative returns ranging from -13.8% to -19.1%, and the company itself is unprofitable with a -$65,021,000 net income over its most recent fiscal year. The pattern of consecutive sell activity by the CEO at a loss-making company warrants attention, though the sales represent only 1.7% of his holdings.

Director Fairmount Funds sold 1,750,000 shares of APGE at $76.30 for $133,525,000.00, reducing stake 85.4% while company reports $-65,021,000.00 net loss.

Fairmount Funds Management LLC (Director) executed a substantial open-market sale on 2026-01-22, reducing its APGE holdings from 2,048,647 shares to 298,647 shares—a -85.4% reduction in stake. The sale at $76.30 represents a $3.56 discount from the current price of $79.86, and occurs in the context of Apogee Therapeutics' negative full-year net income of $-65,021,000.00. Notably, this director's prior trading pattern at APGE shows three well-timed buy transactions on 2023-07-13, each generating positive 90-day returns of +19.8%; however, the same-ticker track record of successful entry timing does not establish predictive value for exit timing, especially given the cross-ticker history shows a 90-day win rate of only 35.71% and a prior single sell in the broader portfolio. The magnitude of this liquidation (1,750,000 shares)—the largest transaction on record for this insider at this ticker—combined with the company's unprofitable status merits investor scrutiny into whether this reflects a material change in conviction or portfolio rebalancing constraints unrelated to operational performance.